Eli Lilly & Co. said Monday it began the first study of an experimental drug derived from a blood sample of an early U.S. survivor of Covid-19, a new effort to take advantage of the molecular defenses developed by recovered patients.

The Indianapolis company said the testing aims to assess the drug’s potential to treat patients hospitalized with the coronavirus.


Read More